Exelixis reported $29.87M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Akebia Therapeutics USD 18.7M 5.68M Sep/2026
Amgen USD 6.39B 169M Sep/2026
AstraZeneca USD 6.93B 362M Jun/2026
Bayer EUR 11.97B 43M Jun/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Cytokinetics USD 807K 427K Sep/2026
Eisai JPY 272.61B 15.06B Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Exelixis USD 29.87M 1.14M Sep/2026
Genmab DKK 21M 8M Mar/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sanofi EUR 24.12B 620M Jun/2026
Takeda JPY 1.44T 6.17B Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026